當前位置：   首頁 > 需求大廳

 >  特色服務 

 >  信息服務 

1.Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone. 2、Supermini NLP (SMP): Material, indicaciones, técnica, ventajas y resultados. 3、A new formulation of etomidate in lipid emulsion--bioavailability and venous provocation 4、Etomidate using a new solubilizer. Experimental clinical studies on venous tolerance and bioavailability 5、中國急性冠狀動脈綜合征防治現(xiàn)狀藍皮書2015   [更多]

上海市計生所需要一份醋酸戈舍瑞林緩釋植入劑的信息   [更多]

1、托伐普坦治療ADPKD臨床實踐指南解讀 2、Severino B, Luisi G, Donomae Iwamoto R, Moreno RA, Perez Teixeira V, Di Vaio P, Saccone I, Magli E, Santagada V, Caliendo G, Mendes GD, De Nucci G. 3、Executive?summary?on?acetaminophen?efficacy?and?safety.?McNeil?Consumer?&?SpecialtyPharmaceuticals.?Data?on?file.?2002-9-19.?Nonprescription?Drugs?Advisory?Committee?Meeting?2002?8?20 4、Polymorphism and pseudopolymorphism on nifedipine 5、Ullmann, vol.18, p.223 1979年的文獻 6、Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in the cynomolgus monkey   [更多]

根據(jù)已知省份、城市的醫(yī)院銷售數(shù)據(jù)樣本，根據(jù)樣本數(shù)據(jù)如何計算醫(yī)院銷售數(shù)據(jù)在全國的銷售量、銷售額？ 放大規(guī)則提供相關原理，思路，計算中所需要的樣本變量（字段，如：如“某藥品的藥品銷售額”與“樣本對于省份”，“樣本城市數(shù)量”、“樣本醫(yī)院數(shù)量”、“樣本醫(yī)院等級比例”等的關系），以及相關規(guī)格參數(shù)以及參數(shù)計算的方式，具體細節(jié)可私下溝通。   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]

1、Effect of probenecid or diet on tebipenem pivoxil tablets pharmacokinetics in healthy male volunteers； 2、Effect of diet on the pharmacokinetics of tebipenem pivoxil fine granules in healthy male volunteers； 3、Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infection 1、Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects. Jin C, Jeon JY, Im YJ, Jeong JA, Kim Y, Chae SW, Bentz J, Kumke T, Kim MG. 7.The control of myopia with atropine.   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國藥典   [更多]

1.Arzneimittel Forschung/Drug research 1986 36(2)，p291-303. 2.The use of antithrombotic drugs in artery disease 3. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer ormation [J]. Diabetes, 2010, 59(Suppll): All(39-OR). 4.Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624. 5.Technology Reports of the Osaka University, , vol. 7, p. 177,182。   [更多]

1、Drugs Fut 1989, 14(9): 875 ISSN 0377-8282 Copyright Clarivate Analytics CCC: 0377-8282 DOI: 10.1358/dof.1989.014.09.103408 2、Dionne, G. (BioChem Pharma Inc.); 1,3-Oxathiolane nucleoside analogues. EP 0526253; JP 1995500317; US 5538975; WO 9303027 . 3、Hoshi, A.; Casta?er, J.; Capecitabine. Drugs Fut 1996, 21, 4, 358 4、Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997, vol. 36, # 9, p. 816 - 818 5、DETERMINATION OF CLENBUTEROL HYDROCHLORIDE BY SEQUENTIAL INJECTION ANALYSIS COUPLED WITH CHEMILUMINESCENCE DETECTION 6、[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations]. 7、Agrati A. M., De Bartolo G., Palmieri G., Minerva Med., 83, 533-536(1992) 8、Dawes J., Hodson B. A., Pepper D. S., Thromb. Haemost, 62, 945-949(1989) 9、with mercury(II) diacetate,trifluoroacetic acid . Acta Chimica Hungarica 1986 vol.122 3-4 p261-272   [更多]